CRISPR THERAPEUTICS AG Cash and Cash Equivalents, Period Increase (Decrease)
CRISPR THERAPEUTICS AG (CRSP) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$75.76 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$13.76M, a 115.83% decline year-over-year.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$18.75M.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$16.61M, a 135.91% decline year-over-year.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$26.65M, a 159.70% decline year-over-year.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$75.76M, a 147.48% decline from fiscal 2016.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for fiscal 2016 was $159.56M, a 2.93% increase from fiscal 2015.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for fiscal 2015 was $155.02M, a 26443.84% increase from fiscal 2014.
- CRISPR THERAPEUTICS AG cash and cash equivalents, period increase (decrease) for fiscal 2014 was $584.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$13.76M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$32.51M derived: sum of 2 quarters · filed 2018-03-08 | -$49.11M derived: sum of 3 quarters · filed 2018-03-08 | -$75.76M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$18.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$35.35M derived: sum of 2 quarters · filed 2017-11-08 | -$62.00M 10-Q · filed 2017-11-08 | $24.91M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | -$16.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$43.26M 10-Q · filed 2017-08-10 | $43.65M derived: sum of 3 quarters · filed 2018-03-08 | $25.41M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | -$26.65M 10-Q · filed 2017-05-11 | $60.26M derived: sum of 2 quarters · filed 2018-03-08 | $42.02M derived: sum of 3 quarters · filed 2018-03-08 | $88.27M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $86.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $68.67M derived: sum of 2 quarters · filed 2018-03-08 | $114.92M derived: sum of 3 quarters · filed 2018-03-08 | $159.56M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$18.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $28.01M derived: sum of 2 quarters · filed 2017-11-08 | $72.65M 10-Q · filed 2017-11-08 | $179.56M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $46.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $90.89M 10-Q · filed 2017-08-10 | $197.80M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $44.64M 10-Q · filed 2017-05-11 | $151.55M derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $106.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $155.02M 10-K · filed 2018-03-08 | ||
| 2015-09-30 | $48.10M 10-Q · filed 2016-11-22 | |||
| 2014-12-31 | $584.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |